Tumor In Vitro Chemosensitivity and Chemoresistance Assays - (0203)

Excluded — Cigna considers all tumor in vitro chemosensitivity/chemoresistance assays (e.g., EDR, MTS/MTT, ChemoFX, ChemoID, MiCK/CorrectChemo, ATP‑CRA, HDRA, ex vivo 3D platforms, RPPA, etc.) experimental, investigational, or unproven and does not cover them. Key requirements: there are no covered indications—claims will be denied if not billed with covered codes/diagnoses and reimbursement is only possible when services are submitted in accordance with applicable Coverage Policy criteria (professional societies advise use only in clinical trials due to insufficient evidence of improved outcomes).

"None — Tumor in vitro chemosensitivity or chemoresistance assays are considered experimental, investigational or unproven."

Sign up to see full coverage criteria, indications, and limitations.